Mobilization of mercury and arsenic in humans by sodium 2,3-dimercapto-1-propane sulfonate (DMPS)

Environmental Health Perspectives

Volumn 106, Issue SUPPL. 4, 1998, Pages 1017-1025

  Aposhian, H Vasken ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Arsenic; Challenge test; Chelation; Chile; DMPS; Mercury

Indexed keywords

ARSENIC; ARSENITE METHYLTRANSFERASE; CHELATING AGENT; DENTAL ALLOY; DRINKING WATER; MERCURY; METAL; METHANEARSONIC ACID; UNCLASSIFIED DRUG; UNITHIOL;

BODY BURDEN; CHELATION; CHILE; CONFERENCE PAPER; CONTROLLED STUDY; DENTAL ASSISTANT; EVOLUTION; GERMANY; HUMAN; HUMAN EXPERIMENT; INTOXICATION; MOBILIZATION; NONHUMAN; NORMAL HUMAN; OCCUPATIONAL EXPOSURE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROVOCATION TEST; URINALYSIS; URINARY EXCRETION; USSR;

EID: 0031687399     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106s41017     Document Type: Conference Paper

References (63)

1. Hecky RE, Ramsey DJ, Bodaly RA, Strange NE. Increased methylmercury contamination in fish in newly formed freshwater reservoirs. In:Advances in Mercury Toxicology (Suzuki T, Imura N, Clarkson TW, eds). New York:Plenum Press, 1991;33-52.
2. Lorscheider FL, Vimy MJ. Evaluation of the safety issue of mercury release from dental fillings. FASEB J 7:1432-1433 (1993).
3. 3:Aposhian HV, Bruce DC, Alter W, Dart RC, Hurlbut KM, Aposhian MM. Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid:correlation with dental amalgam score. FASEB J 6:2472-2476 (1992).
4. Clarkson TW, Friberg L, Hursh JB, Nylander M. The prediction of intake of mercury vapor from amalgams. In:Biological Monitoring of Toxic Metals (Clarkson TW, Friberg L, Nordberg GF, Sager PR, eds). New York:Plenum Press, 1988;247-260.
5. Summers AO, Wireman J, Vimy MJ, Lorscheider FL, Marshall B, Levy SB, Bennett S, Billard L, Mercury released from dental "silver" fillings provokes an increase in mercury- and antibiotic-resistant bacteria in oral and intestinal floras of primates. Antimicrob Agents Chemother 37:825-834 (1993).
6. U.S. Centers for Disease Control. Preventing Lead Poisoning in Young Children. Atlanta, GA:U.S. Department of Health and Human Services, 1991.
7. National Health and Environmental Effects Research Laboratory. Workshop on Developing and Epidemiology Research Strategy for Arsenic in Drinking Water (Work Assignment 1-12, Contract no 68-D2-0187). Research Triangle Park, NC:National Health and Environmental Effects Research Laboratory, 1994.
8. Sancha AM, Vega F, Venturino H, Fuentes S, Salazar AM, Moreno V, Baron AM, Rodriguez D. The arsenic health problem in northern Chile evaluation and control. A case study preliminary report. In:Proceedings of the International Seminar. Arsenic in the Environment and Its Incidence on Health. Santiago, Chile:Universidad de Chile, 1992;187-202.
9. Aposhian HV, Arroyo A, Cebrian ME, Del Razo LM, Hurlbut KM, Dart RC, Gonzalez-Ramirez D, Kreppel H, Speisky H, Smith A, et al. DMPS-arsenic challenge test. I:Increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate. J Pharmacol Exp Ther 277:938-944 (1997).
10. Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE. Methylation study in a population environmentally exposed to high arsenic drinking water. Environ Health Perspect 104:1200-1207 (1996).
11. Cebrian ME, Albores A, Aguilar M, Blakely E. Chronic arsenic poisoning in the north of Mexico. Hum Toxicol 2:121-133 (1983).
12. Vahter M, Concha G, Nermell B, Nilsson R, Duluot F, Natajaran A. A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol 293:455-462 (1995).
13. Guha Mazumder DN, Chakraborty AK, Ghose A, Gupta JD, Chakraborty DP, Dey SB. Chronic arsenic toxicity from drinking water in rural West Bengal. Bull World Health Org 66:499-506 (1988).
14. Chatterjee A, Das D, Mandal BK, Chowdhury TR, Samanta G, Chakraborty, D. Arsenic in ground water in six districts of West Bengal, India:the biggest arsenic calamity in the world. Part 1:Arsenic species in drinking water and urine of the affected people. Analyst 120:643-650 (1995).
15. Luo ZD, Zhang YM, Ma L, Zhang ZY, He X, Wilson R, Byrd DM, Griffiths JG, Lai S, He L, et al. Chronic arsencism and cancer in Inner Mongolia - consequences of well-water arsenic levels greater than 50 μg/l In:Arsenic:Exposure and Health Effects (Abernathy CO, Claderon RL, Chappell WR, eds). London:Chapman & Hall, 1997;55-68.
16. Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a Blackfoot disease-endemic area in Taiwan:high-arsenic artesian well water and cancers. Cancer Res 45:5895-5899 (1985).
17. Kemper FH, Jekat FW, Bertram HP, Eckard R. New chelating agents. In:Basic Science in Toxicology (Volans GM, Sims J, Sullivan FM, Turner P, eds). London:Taylor & Francis, 1990;523-546.
18. Maiorino RM, Weber GL, Aposhian HV. Fluorometric determination of 2,3-dimercaptopropane-1-sulfonic acid and other dithiols by precolumn derivization with bromobimane and column liquid chromatography. J Chromatogr 374:297-310 (1986).
19. Maiorino RM, Barry TJ, Aposhian HV. Determination and metabolism of dithiol-chelating agents. Electrolytic and chemical reduction of oxidized dithiols in urine. Anal Biochem 160:217-226 (1987).
20. Maiorino RM, Aposhian HV. Determination and metabolism of dithiol chelating agents. IV:Urinary excretion of meso-23,-dimercaptosuccinic acid and mercaptosuccinic acid in rabbits given meso-2,3-dimercaptosuccinic acid. Biochem Pharmacol 38:1147-1154 (1989).
21. Rivera M, Zheng W, Aposhian HV, Fernando Q. Determination and metabolism of dithiol chelating agents. VIII:Metal complexes of meso-dimercaptosuccinic acid. Toxicol Appl Pharmacol 100:96-106 (1989).
22. Maiorino RM, Dart RC, Carter DF, Aposhian HV. Determination and metabolism of dithiol chelating agents. XII:Metabolism and pharmacokinetics of sodium 2,3-dimercaptopropane-1-sulfonate in humans. J Pharmacol Exp Ther 259:808-814 (1991).
23. Aposhian HV, Maiorino RM, Dart RC, Perry DF. Urinary excretion of meso-2,3-dimercaptosuccinic acid inhuman subjects. Clin Pharmacol Ther 45:520-526 (1989).
24. Maiorino RM, Bruce DC, Aposhian HV. Determination and metabolism of dithiol chelating agents. VI:Isolation and identification or the mixed disulfides of meso-2,3-dimercaptosuccinic acid with 1-cysteine in human urine. Toxicol Appl Pharmacol 97:338-349 (1989).
25. Hurlbut KM, Maiorino RM, Mayersohn M, Dart RC, Bruce DC, Aposhian HV. Determination and metabolism of dithiol chelating agents. XVI:Pharmacokinetics of 2,3-dimercaptopropanesulfonate after intravenous administration to human volunteers. J Pharmacol Exp Ther 268:662-668 (1994).
26. Gonzalez-Ramirez D, Maiorino RM, Zuniga-Charles M, Xu Z, Hurlbut KM, Junco-Munoz P, Aposhian MM, Dart RC, Diaz Gama JH, Echeverria D, et al. Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. II:Urinary mercury, porphyrins and neurobehavioral changes of dental workers in Monterrey, Mexico. J Pharmacol Exp Ther 272:264-274 (1995).
27. Maiorino RM, Gonzalez-Ramirez D, Zuniga-Charles M, Xu ZF, Hurlbut KM, Aposhian MM, Dart RC, Woods JS, Ostrosky-Wegman P, Gonsebatt ME, et al. Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. III:Urinary mercury after exposure to mercurous chloride. J Pharmacol Exp Ther 277:938-944 (1996).
28. Aaseth J, Jacobsen D, Anderson O, Wickstrom E. Treatment of mercury and lead poisonings with dimercapto succinic acid and sodium dimercaptopropanesulfonate:a review. Analyst 120:853-854 (1995).
29. Aposhian HV, Gonzalez-Ramirez D, Maiorino RM, Zuniga-Charles M, Xu ZF, Hurlbut KM, Junco-Munoz P, Aposhian MM, Dart RC. Mobilization of heavy metals by newer, thetapeutically useful chelating agents. Toxicology 97:23-38 (1995).
30. Aposhian HV. DMSA and DMPS - water soluble antidotes for heavy metal poisoning. Annu Rev Pharmacol Toxicol 23:193-215 (1983).
31. Aposhian HV, Aposhian MM. Meso-2,3-dimercaptosuccinic acid:chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu Rev Toxicol 30:279-306 (1990).
32. Angle CR. Childhood lead poisoning and its treatment. Annu Rev Pharmacol Toxicol 33:409-434 (1993).
33. Klaassen CD. Heavy metals and heavy-metal antagonists. In:The Pharmacological Basis of Therapeutics (Gilman AG, Goodman LS, Rall TW, Murad F, eds). New York:Macmillan, 1985;1605-1627.
34. Petrunkin VE. Synthesis and properties of dimercapto derivatives of alkylsulfonic acids. Ukr Biokhim Zh 22:603-607 (1956).
35. Klimova LK. Pharmacology of a new unithiol antidote. Farmakol Toksikol Mosc 21:53-59 (1958).
36. Rote Liste. Azneimittelverzeichnis des BPI. Bundesverban der Pharmazeutischen Industrie e.V.:Frankfurt, 12-003;12-005 (1995).
37. Enwonwu CO. Potential health hazard of use of mercury in dentistry:critical review of the literature. Environ Res 42:257-274 (1987).
38. Wildenauer DB, Reuther H, Weger N. Interactions of the chelating agent 2,3-dimercaptopropane-1-sulfonate with red blood cells in vitro. I:Evidence For carrier mediated transport. Chem Biol Interact 42:165-177 (1982).
39. Zheng W, Maiorino RM, Brendel K, Aposhian HV. Determination and metabolism of dithiol chelating agents. IV:Biliary excretion of dithiols and their interactions with cadmium and metallothionein. Fundam Appl Toxicol 14:598-607 (1990).
40. Schiele R, Schaller KH. Einsatz des Komplexbildners DMPS (Dimaval) zur Feststellung von Quecksilber-Speicherungen. In:Berufskrankheiten, Krebserzeugende Arbeitsstoffe, Biological Monitoring, Verhandlungen der Deutschen Gesellschaft für Arbeitsmedizin e.V., 30 Jahrestagung (Schuckmann F, Schopper-Jochum S, eds). Stuttgart:Gentner Verlag, 1990;379-382.
41. Zinke T. Amalgame aus der Sicht des Bundesgesundheitsamtes. Zahnärztl Mitteilungen 81(22):2238-2243 (1991).
42. U.S. DHHS, PHS. Dental Amalgam:A Scientific Review and Recommended Public Health Service Strategy for Research. Washington:U.S. Department of Health and Human Services, Public Health Service, 1993.
43. Schiele R, Kroncke A. Mercury mobility through DMPS (Dimaval) in persons with and without amalgam fillings [German]. Zahnarztliche Mitteilungen 79:1866-1868 (1989).
44. Molin M, Schutz A, Skerfving S, Sallsten G. Mobilized mercury in subjects with varying exposure to elemental mercury vapour. Int Arch Occup Environ Health 63:187-192 (1991).
45. Vahter M. Species differences in the metabolism of arsenic compounds. Appl Organomet Chem 8:175-182 (1994).
46. Offergelt JA, Roels H, Buchet JP, Boeckx M, Lauwerys R. Relation between airborne arsenic trioxide and urinary excre- tion of inorganic arsenic and its methylated metabolites. Br J Ind Med 49:387 (1992).
47. Yamauchi H, Takahashi K, Mashiko M, Saitoh J, Yamamura Y. Intake of different chemical species of dietary arsenic by Japanese, and their blood and urinary arsenic levels. Appl Organomet Chem 6:383 (1992).
48. Hopenhayn-Rich C, Smith AH, Goeden MM. Human studies do not support the methylation threshold hypothesis for the toxicity of inorganic arsenic. Environ Res 60:161-177 (1993).
49. Zakharyan RA., Wildfang E, Aposhian HV. Enzymatic methylation of arsenic compounds. III:The marmoset and tamarin, but not the rhesus, monkey are deficient in methyltransferases that methylate inorganic arsenic. Toxicol Appl Pharmacol 140:77-84 (1996).
50. Healy SM, Zakharyan RA, Aposhian HV. Enzymatic methylation of arsenic compounds. IV:In vitro and in vivo deficiency of the methylation of arsenite and monomethylarsonic acid in the guinea pig. Mutat Res 386:229-239 (1997).
51. Aposhian HV. Methyltransferases of As species. Annu Rev Pharmacol Toxicol 37:397-419 (1997).
52. 74As-arsenite. Arch Toxicol 51:65-77 (1982).
53. Vahter M, Marafante E. Reduction and binding of arsenate in marmoset monkeys. Arch Toxicol 57:119-124 (1985).
54. Vahter M, Couch R, Nermell B, Nilsson R. lack of methylation of inorganic arsenic in the chimpanzee. Toxicol Appl Pharmacol 133:262-268 (1995).
55. Zakharyan RA, Wu Y, Bogdan CM, Aposhian HV. Enzymatic methylation of arsenic compounds. I:Assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Chem Res Toxicol 8:1029-1038 (1995).
56. Wildfang EK, Healy SM, Radabaugh TR, Badghisi H, Zakharyan RA, Aposhian HV. Enzymatic methylation of arsenic compounds. V:Does evolutionary selection explain the lack of in vitro methylation of arsenite in some New World species? Toxicol Appl Pharmacol (in press).
57. Fairlamb AH, Cerami A. Identification of a novel, thiol containing cofactor essential for glutathione reductase enzyme activity in trypanomatids. Mol Biochem Parasitol 14:187-198 (1985).
58. Fairlamb AH, Henderson GB, Cerami A. Trypanothione is the primary target for arsenical drugs against African trypanosomes, Proc Natl Acad Sci USA 86:2607-2611 (1989).
59. Buchet JP, Lauwerys R. Study of inorganic arsenic methylation by rat liver in vitro:relevance for the interpretation of observations in man. Arch Toxicol 57:125-129 (1985).
60. Buchet JP, Lauwerys R. Role of thiols in the in vitro methylation of inorganic arsenic by rat liver cytosol. Biochem Pharmacol 37:3149-3153 (1988).
61. Styblo M, Yamauchi H, Thomas DJ. Comparative in vitro methylation of trivalent and pentavalent arsenicals. Toxicol Appl Pharmacol 135:172-178 (1995).
62. Styblo M, Delnomdedieu M, Thomas DJ. Mono- and dimethylation of arsenic in rat liver cytosol in vitro. Chem Biol Interact 99:147-164 (1996).
63. Villanacci JF, Beauchamp R, Perrotta DM, Hendricks K, Rodriguez M, Dutton RJ, Sutton K, Simpson DM, Richards K, Nelson F, et al. Mercury poisoning associated with beauty cream - Texas, New Mexico, and California, 1995-1996. Arch Dermatol 132:1533-1534 (1996).